{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:08:47Z","timestamp":1781953727997,"version":"3.54.5"},"reference-count":178,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973233"],"award-info":[{"award-number":["81973233"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong","doi-asserted-by":"publisher","award":["2021C02062"],"award-info":[{"award-number":["2021C02062"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008043","name":"Zhejiang Sci-Tech University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008043","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejmech.2023.115151","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T20:12:18Z","timestamp":1674850338000},"page":"115151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Treatment of allergy: Overview of synthetic anti-allergy small molecules in medicinal chemistry"],"prefix":"10.1016","volume":"249","author":[{"given":"Shanshan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansar","family":"Javeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiqin","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shandong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingnan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115151_bib1","doi-asserted-by":"crossref","first-page":"6253","DOI":"10.1007\/s00216-021-03580-5","article-title":"An integrated strategy for the identification and screening of anti-allergy components from natural products based on calcium fluctuations and cell extraction coupled with HPLC\u2013Q\u2013TOF\u2013MS","volume":"413","author":"Hu","year":"2021","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib2","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1016\/j.csbj.2021.08.012","article-title":"Computationally grafting an IgE epitope onto a scaffold: implications for a pan anti-allergy vaccine design","volume":"19","author":"Sabban","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.ejmech.2023.115151_bib3","unstructured":"DataBridge, https:\/\/www.databridgemarketresearch.com\/reports\/global-antiallergics-drugs-market."},{"key":"10.1016\/j.ejmech.2023.115151_bib4","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jaci.2018.02.003","article-title":"Mechanism for initiation of food allergy: dependence on skin barrier mutations and environmental allergen costimulation","volume":"141","author":"Walker","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib5","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jaip.2017.01.016","article-title":"Association of clinical reactivity with sensitization to allergen components in multifood-allergic children","volume":"5","author":"Andorf","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib6","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/all.13319","article-title":"EAACI Allergen Immunotherapy Guidelines Group.EAACI guidelines on allergen immunotherapy: IgE-mediated food allergy. , EAACI guidelines on allergen immunotherapy: IgE-mediated food allergy","volume":"73","author":"Pajno","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.ejmech.2023.115151_bib7","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3594210","article-title":"Recent progress in traditional Chinese medicines and their mechanism in the treatment of allergic rhinitis","volume":"2022","author":"Mao","year":"2022","journal-title":"J. Health. Eng."},{"key":"10.1016\/j.ejmech.2023.115151_bib8","first-page":"54","article-title":"Trend analysis of anti-allergic medicines during the 11-year period in Iran (2006-2017)","volume":"59","author":"Faraji","year":"2021","journal-title":"Acta Med. Iran."},{"key":"10.1016\/j.ejmech.2023.115151_bib9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nri2275","article-title":"Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma","volume":"8","author":"Hammad","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib10","doi-asserted-by":"crossref","first-page":"G381","DOI":"10.1152\/ajpgi.00357.2012","article-title":"IL-33-induced alterations in murine intestinal function and cytokine responses are MyD88, STAT6, and IL-13 dependent","volume":"304","author":"Yang","year":"2013","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.ejmech.2023.115151_bib11","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1002\/eji.200940026","article-title":"IL\u201033 broadens its repertoire to affect DC","volume":"39","author":"Turnquist","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib12","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.4049\/jimmunol.1303026","article-title":"The immunology of food allergy","volume":"192","author":"Johnston","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib13","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature07204","article-title":"The development of allergic inflammation","volume":"454","author":"Galli","year":"2008","journal-title":"Nature (Lond.)"},{"key":"10.1016\/j.ejmech.2023.115151_bib14","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nri.2016.111","article-title":"Food allergy: immune mechanisms, diagnosis and immunotherapy","volume":"16","author":"Yu","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib15","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.chest.2017.07.033","volume":"153","author":"LoVerde","year":"2018","journal-title":"Anaphylaxis, Chest"},{"key":"10.1016\/j.ejmech.2023.115151_bib16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jaci.2017.11.007","article-title":"Food allergy and omics","volume":"141","author":"Dhondalay","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2017.11.004","article-title":"Treatment for food allergy","volume":"141","author":"Burks","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib18","series-title":"Food Allergy: Molecular Basis and Clinical Practice","first-page":"209","article-title":"Nutritional aspects and diets in food allergy","volume":"vol. 101","author":"Nowak-W\u0119grzyn","year":"2015"},{"key":"10.1016\/j.ejmech.2023.115151_bib19","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.3389\/fimmu.2018.01873","article-title":"The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: the hunt for new therapeutic targets","volume":"9","author":"Thangam","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib20","series-title":"Middleton's Allergy: Principles Practice","author":"Busse","year":"2003"},{"key":"10.1016\/j.ejmech.2023.115151_bib21","first-page":"1337","article-title":"Nonsedating antihistamines: pharmacology, clinical efficacy and adverse effects","volume":"45","author":"Kaliner","year":"1992","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.ejmech.2023.115151_bib22","doi-asserted-by":"crossref","first-page":"S307","DOI":"10.1016\/S0091-6749(96)80116-3","article-title":"Clinical comparison of histamine H1\u2013receptor antagonist drugs","volume":"98","author":"Du Buske","year":"1996","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib23","first-page":"407","article-title":"Safety and efficacy of loratadine (Sch-29851): a new non-sedating antihistamine in seasonal allergic rhinitis","volume":"58","author":"Dockhorn","year":"1987","journal-title":"Ann. Allergy"},{"key":"10.1016\/j.ejmech.2023.115151_bib24","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1398-9995.1998.tb03933.x","article-title":"Changes in skin\u2010test reactivity do not correlate with clinical efficacy of H1\u2010blockers in seasonal allergic rhinitis","volume":"53","author":"Bousquet","year":"1998","journal-title":"Allergy"},{"key":"10.1016\/j.ejmech.2023.115151_bib25","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/0091-6749(88)90948-7","article-title":"Comparison of the efficacy and safety of loratadine, terfenadine, and placebo in the treatment of seasonal allergic rhinitis","volume":"81","author":"Gutkowski","year":"1988","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2165\/00003495-198937010-00003","volume":"37","author":"Clissold","year":"1989","journal-title":"Loratadine, Drugs"},{"key":"10.1016\/j.ejmech.2023.115151_bib27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1398-9995.1990.tb00493.x","article-title":"A multicentre study of loratadine, clemastine and placebo in patients with perennial allergic rhinitis","volume":"45","author":"Fr\u00f8ulund","year":"1990","journal-title":"Allergy"},{"key":"10.1016\/j.ejmech.2023.115151_bib28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0091-6749(87)80197-5","article-title":"Sedative effects of antihistamines","volume":"80","author":"Roth","year":"1987","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib29","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1081-1206(10)61566-9","article-title":"Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic","volume":"92","author":"Verster","year":"2004","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF03259406","article-title":"New data on the safety of loratadine","volume":"4","author":"Van Cauwenberge","year":"1992","journal-title":"Drug Invest."},{"key":"10.1016\/j.ejmech.2023.115151_bib31","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1081-1206(10)62979-1","article-title":"Evaluation of the potential cardiotoxicity of the antihistamines terfenadine, astemizole, loratadine, and cetirizine in atopic children","volume":"80","author":"Delgado","year":"1998","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib32","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1365-2125.1992.tb05638.x","article-title":"Assessment of the anticholinergic effect of the new antihistamine mizolastine in healthy subjects","volume":"34","author":"Danjou","year":"1992","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115151_bib33","first-page":"135","article-title":"Pharmacodynamics and pharmacokinetics of mizolastine (SL 85.0324), a new nonsedative H1 antihistamine","volume":"69","author":"Rosenzweig","year":"1992","journal-title":"Ann. Allergy"},{"key":"10.1016\/j.ejmech.2023.115151_bib34","first-page":"551","article-title":"In vivo and in vitro interaction of the novel selective histamine H1 receptor antagonist mizolastine with H1 receptors in the rodent","volume":"45","author":"Benavides","year":"1995","journal-title":"Arzneimittel forschung."},{"key":"10.1016\/j.ejmech.2023.115151_bib35","first-page":"173","article-title":"Anti-inflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat","volume":"48","author":"Pichat","year":"1998","journal-title":"Arzneim. Forsch."},{"key":"10.1016\/j.ejmech.2023.115151_bib36","first-page":"559","article-title":"Anti-anaphylactic activity of the novel selective histamine H1 receptor antagonist mizolastine in the rodent","volume":"45","author":"Levrier","year":"1995","journal-title":"Arzneimittel forschung."},{"key":"10.1016\/j.ejmech.2023.115151_bib37","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.1365-2222.1999.0290s3206.x","article-title":"QT interval monitoring during clinical studies with mizolastine, a new H1 antihistamine","volume":"29","author":"Delauche\u2010Cavallier","year":"1999","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.ejmech.2023.115151_bib38","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1365-2125.1999.00927.x","article-title":"Study of cardiac repolarization in healthy volunteers performed with mizolastine, a new H1-receptor antagonist","volume":"47","author":"Chaufour","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115151_bib39","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2222.1992.tb03085.x","article-title":"The effect of azelastine on the early allergic response","volume":"22","author":"Shin","year":"1992","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.ejmech.2023.115151_bib40","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s00011-003-1193-5","article-title":"Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin","volume":"52","author":"Denham","year":"2003","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.ejmech.2023.115151_bib41","first-page":"615","article-title":"Ebastine in perennial allergic rhinitis","volume":"67","author":"Jm","year":"1991","journal-title":"Ann. Allergy"},{"key":"10.1016\/j.ejmech.2023.115151_bib42","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1034\/j.1398-9995.1999.00984.x","article-title":"A 12\u2010week, placebo\u2010controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis","volume":"54","author":"Bousquet","year":"1999","journal-title":"Allergy"},{"key":"10.1016\/j.ejmech.2023.115151_bib43","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/BF03259166","article-title":"Efficacy and tolerability of ebastine at two dose levels in the treatment of seasonal allergic rhinitis","volume":"1","author":"De Molina","year":"1989","journal-title":"Drug Invest."},{"key":"10.1016\/j.ejmech.2023.115151_bib44","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2796.1989.tb01424.x","article-title":"A double\u2010blind placebo\u2010controlled study of the efficacy and tolerability of ebastine against hayfever in general practice patients","volume":"226","author":"Ankier","year":"1989","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ejmech.2023.115151_bib45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2165\/00003495-199600521-00006","article-title":"Clinical studies of the efficacy and tolerability of ebastine 10 or 20mg once daily in the treatment of seasonal allergic rhinitis in the US","volume":"52","author":"Storms","year":"1996","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2023.115151_bib46","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2165\/00003495-199600521-00007","article-title":"Comparison of the efficacy of ebastine 10mg and 20mg once daily with that of cetirizine 10mg once daily in adults with seasonal allergic rhinitis","volume":"52","author":"Cohen","year":"1996","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2023.115151_bib47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00314920","article-title":"Placebo controlled comparison of acute effects of ebastine and clemastine on performance and EEG","volume":"42","author":"Hopes","year":"1992","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115151_bib48","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF01740667","article-title":"Lack of pharmacodynamic and pharmacokinetic interactions of the antihistamine ebastine with ethanol in healthy subjects","volume":"43","author":"Mattila","year":"1992","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115151_bib49","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.0901-9928.2001.890405.x","article-title":"Preclinical comparison of ebastine and other second generation H1\u2010antihistamines","volume":"89","author":"Yakuo","year":"2001","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2023.115151_bib50","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0091-6749(05)80210-6","article-title":"A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects","volume":"86","author":"Estelle","year":"1990","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2222.1990.tb02663.x","article-title":"Effect of cetirizine in a conjunctival provocation test with allergens","volume":"20","author":"Schoeneich","year":"1990","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.ejmech.2023.115151_bib52","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0091-6749(96)70155-0","article-title":"Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire","volume":"98","author":"Bousquet","year":"1996","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib53","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2222.1993.tb02487.x","article-title":"Treatment of mosquito bites with cetirizine","volume":"23","author":"Reunala","year":"1993","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.ejmech.2023.115151_bib54","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/BF00280119","article-title":"Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving","volume":"42","author":"Ramaekers","year":"1992","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115151_bib55","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/00003495-199346060-00008","volume":"46","author":"Spencer","year":"1993","journal-title":"Cetirizine Drug."},{"key":"10.1016\/j.ejmech.2023.115151_bib56","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/ajhp\/54.4.342","article-title":"FDA announces plan to halt marketing of terfenadine","volume":"54","year":"1997","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ejmech.2023.115151_bib57","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s000110300050","article-title":"H1 antagonists: receptor affinity versus selectivity","volume":"52","author":"Gillard","year":"2003","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.ejmech.2023.115151_bib58","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/BF01990945","article-title":"Levocabastine: pharmacological profile of a highly effective inhibitor of allergic reactions","volume":"35","author":"Awouters","year":"1992","journal-title":"Agents Actions"},{"key":"10.1016\/j.ejmech.2023.115151_bib59","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF01206245","article-title":"Tolerability of levocabastine eye drops","volume":"84","author":"Janssens","year":"1993","journal-title":"Doc. Ophthalmol."},{"key":"10.1016\/j.ejmech.2023.115151_bib60","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2222.1991.tb03197.x","article-title":"Double\u2010blind comparison of levocabastine eye drops with sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis","volume":"21","author":"Azevedo","year":"1991","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.ejmech.2023.115151_bib61","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1398-9995.1993.tb01108.x","article-title":"Topical levocabastine is more effective than sodium cromoglycate for the prophylaxis and treatment of seasonal allergic conjunctivitis","volume":"48","author":"Davies","year":"1993","journal-title":"Allergy"},{"key":"10.1016\/j.ejmech.2023.115151_bib62","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2222.1991.tb01755.x","article-title":"Levocabastine: an effective topical treatment of allergic rhinoconjunctivitis","volume":"21","author":"Janssens","year":"1991","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.ejmech.2023.115151_bib63","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1398-9995.1985.tb00255.x","article-title":"A double\u2010blind evaluation of topical levocabastine, a new specific H1 antagonist in patients with allergic conjunctivitis","volume":"40","author":"Pipkorn","year":"1985","journal-title":"Allergy"},{"key":"10.1016\/j.ejmech.2023.115151_bib64","first-page":"25","article-title":"The effect of levocabastine nasal spray in nasal provocation tests","volume":"8","author":"Palma-Carlos","year":"1988","journal-title":"Int. J. Clin. Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2023.115151_bib65","first-page":"121","article-title":"Intranasal levocabastine for the treatment of seasonal allergic rhinitis: a multicentre, double-blind, placebo-controlled trial","volume":"33","author":"Dahl","year":"1995","journal-title":"Rhinolophe"},{"key":"10.1016\/j.ejmech.2023.115151_bib66","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-2125.1986.tb02907.x","article-title":"Comparison of levocabastine, a new selective H1\u2010receptor antagonist, and disodium cromoglycate, in a nasal provocation test with allergen","volume":"22","author":"Kolly","year":"1986","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115151_bib67","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/0091-6749(91)90136-C","article-title":"Levocabastine nasal spray better than sodium cromoglycate and placebo in the topical treatment of seasonal allergic rhinitis","volume":"87","author":"Schata","year":"1991","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib68","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2165\/00003495-199141020-00006","volume":"41","author":"Dechant","year":"1991","journal-title":"Levocabastine Drugs."},{"key":"10.1016\/j.ejmech.2023.115151_bib69","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1398-9995.1990.tb00531.x","article-title":"Absence of central effects with levocabastine eye drops","volume":"45","author":"Arriaga","year":"1990","journal-title":"Allergy"},{"key":"10.1016\/j.ejmech.2023.115151_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119551","article-title":"Pro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across Europe","volume":"10","author":"Poluzzi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115151_bib71","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0091-6749(82)80002-X","article-title":"Pharmacologic modulation of the whealing response to histamine in human skin: identification of doxepin as a potent in vivo inhibitor","volume":"69","author":"Sullivan","year":"1982","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib72","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1136\/bmj.317.7173.1624","article-title":"Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials","volume":"317","author":"Weiner","year":"1998","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejmech.2023.115151_bib73","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1081-1206(10)63057-8","article-title":"Continuous versus on demand treatment with cetirizine for allergic rhinitis","volume":"79","author":"Ciprandi","year":"1997","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib74","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1081-1206(10)63023-2","article-title":"Azelastine nasal spray as adjunctive therapy to azelastine tablets in the management of seasonal allergic rhinitis","volume":"79","author":"Weiler","year":"1997","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib75","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature10236","article-title":"Structure of the human histamine H1 receptor complex with doxepin","volume":"475","author":"Shimamura","year":"2011","journal-title":"Nature (Lond.)"},{"key":"10.1016\/j.ejmech.2023.115151_bib76","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1096\/fj.15-278010","article-title":"Time\u2010resolved in situ assembly of the leukotriene\u2010synthetic 5\u2010lipoxygenase\/5\u2010lipoxygenase\u2010activating protein complex in blood leukocytes","volume":"30","author":"Gerstmeier","year":"2016","journal-title":"FASEB"},{"key":"10.1016\/j.ejmech.2023.115151_bib77","first-page":"1841","volume":"357","author":"Peters-Golden","year":"2007","journal-title":"J. Med."},{"key":"10.1016\/j.ejmech.2023.115151_bib78","first-page":"9","article-title":"Mechanisms of allergic diseases in Otorhinolaryngology","volume":"32","author":"Ridolo","year":"2018","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.ejmech.2023.115151_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2021.100969","article-title":"Corticosteroid resistance in asthma: cellular and molecular mechanisms","volume":"85","author":"Caramori","year":"2022","journal-title":"Mol. Aspect. Med."},{"key":"10.1016\/j.ejmech.2023.115151_bib80","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.plipres.2010.12.001","article-title":"Recent progress in phospholipase A2 research: from cells to animals to humans","volume":"50","author":"Murakami","year":"2011","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.ejmech.2023.115151_bib81","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1080\/14656566.2020.1807514","article-title":"Advances with glucocorticoids in the treatment of asthma: state of the art","volume":"21","author":"Ora","year":"2020","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2023.115151_bib82","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejmech.2017.10.020","article-title":"Recent advances in the search for novel 5-lipoxygenase inhibitors for the treatment of asthma","volume":"153","author":"Bruno","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib83","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jaci.2006.01.032","article-title":"Update on glucocorticoid action and resistance","volume":"117","author":"Ito","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib84","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.bbalip.2018.11.009","article-title":"Function of secreted phospholipase A2 group-X in asthma and allergic disease","volume":"1864","author":"Nolin","year":"2019","journal-title":"Biochim. Biophys. Acta, Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.ejmech.2023.115151_bib85","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/164_2016_62","volume":"237","author":"Barnes","year":"2017","journal-title":"Glucocorticosteroids, Handb Exp. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115151_bib86","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1146\/annurev.iy.07.040189.000423","article-title":"Heterogeneity of mast cells and phenotypic change between subpopulations","volume":"7","author":"Kitamura","year":"1989","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib87","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ni1158","article-title":"Mast cells in the development of adaptive immune responses","volume":"6","author":"Galli","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib88","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jaci.2004.04.015","article-title":"The mastocyte: the \u201cother\u201d inflammatory cell in immunopathogenesis","volume":"114","author":"Mekori","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib89","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri1460","article-title":"Mast-cell responses to pathogens","volume":"4","author":"Marshall","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib90","article-title":"Mast cells","volume":"77","author":"Ya","year":"1997","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2023.115151_bib91","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0021-9258(18)53916-8","article-title":"Ca (2+)-dependent and Ca (2+)-independent isozymes of protein kinase C mediate exocytosis in antigen-stimulated rat basophilic RBL-2H3 cells. Reconstitution of secretory responses with Ca2+ and purified isozymes in washed permeabilized cells","volume":"268","author":"Ozawa","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib92","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood-2005-06-2271","article-title":"Fc\u03b5R1 and toll-like receptors mediate synergistic signals to markedly augment production of inflammatory cytokines in murine mast cells","volume":"107","author":"Qiao","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2023.115151_bib93","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1096\/fj.06-6016fje","article-title":"Ca2+ influx through CRAC channels activates cytosolic phospholipase A2, leukotriene C4 secretion, and expression of c\u2010fos through ERK\u2010dependent and independent pathways in mast cells","volume":"20","author":"Chang","year":"2006","journal-title":"FASEB"},{"key":"10.1016\/j.ejmech.2023.115151_bib94","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-065X.2009.00807.x","article-title":"IP3 receptors: some lessons from DT40 cells","volume":"231","author":"Taylor","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejmech.2023.115151_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0143-4160(86)90026-6","article-title":"A model for receptor-regulated calcium entry","volume":"7","author":"Putney","year":"1986","journal-title":"Cell Calcium"},{"key":"10.1016\/j.ejmech.2023.115151_bib96","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0304-4157(75)90017-9","article-title":"Inositol phospholipids and cell surface receptor function","volume":"415","author":"Michell","year":"1975","journal-title":"Biochim. Biophys. Acta Rev. Biomembr."},{"key":"10.1016\/j.ejmech.2023.115151_bib97","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.14850","article-title":"Calcium influx through CRAC channels controls actin organization and dynamics at the immune synapse","volume":"5","author":"Hartzell","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.ejmech.2023.115151_bib98","doi-asserted-by":"crossref","first-page":"6667","DOI":"10.4049\/jimmunol.177.10.6667","article-title":"Cytokines expression of mast cell-derived NFAT transcription factors in the expression of mast cell-derived cytokines","volume":"177","author":"Schild","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib99","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/jcb.22013","article-title":"Arachidonic acid release by H2O2 mediated proliferation of mouse embryonic stem cells: involvement of Ca2+\/PKC and MAPKs\u2010induced EGFR transactivation","volume":"106","author":"Lee","year":"2009","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ejmech.2023.115151_bib100","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.taap.2008.07.019","article-title":"Involvement of MAPKs, NF-kappaB and p300 co-activator in IL-1beta-induced cytosolic phospholipase A2 expression in canine tracheal smooth muscle cells, Toxicol","volume":"232","author":"Luo","year":"2008","journal-title":"Appl. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115151_bib101","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2353\/ajpath.2008.070559","article-title":"Mast cells regulate the magnitude and the cytokine microenvironment of the contact hypersensitivity response","volume":"172","author":"Norman","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejmech.2023.115151_bib102","first-page":"127","article-title":"Amelioration of anaphylaxis, mast cell degranulation and bronchospasm by Euphorbia hirta L. extracts in experimental animals, Beni","volume":"7","author":"Parmar","year":"2018","journal-title":"Suef. Univ. J. Basic. Appl. Sci."},{"key":"10.1016\/j.ejmech.2023.115151_bib103","doi-asserted-by":"crossref","first-page":"252","DOI":"10.5958\/0974-360X.2017.00052.X","article-title":"Bronchodilator and mast cell stabilizer effect of siddha formulation seenthil chooranam","volume":"10","author":"Vijayalakshmi","year":"2017","journal-title":"Res. J. Pharm. Technol."},{"key":"10.1016\/j.ejmech.2023.115151_bib104","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature (Lond.)"},{"key":"10.1016\/j.ejmech.2023.115151_bib105","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1084\/jem.20020018","article-title":"Accumulation of immature Langerhans cells in human lymph nodes draining chronically inflamed skin","volume":"196","author":"Geissmann","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2023.115151_bib106","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1080\/10408398.2019.1650716","article-title":"An overview on marine anti-allergic active substances for alleviating food-induced allergy","volume":"60","author":"Wang","year":"2020","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"10.1016\/j.ejmech.2023.115151_bib107","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","article-title":"The cytokines of asthma","volume":"50","author":"Lambrecht","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ejmech.2023.115151_bib108","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.4049\/jimmunol.160.8.4090","article-title":"Dendritic cells are required for the development of chronic eosinophilic airway inflammation in response to inhaled antigen in sensitized mice","volume":"160","author":"Lambrecht","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib109","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.4049\/jimmunol.1003636","article-title":"Chronic helminth infection promotes immune regulation in vivo through dominance of CD11cloCD103\u2212 dendritic cells","volume":"186","author":"Smith","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib110","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1164\/rccm.201101-0019OC","article-title":"Persistent activation of dendritic cells after resolution of allergic airway inflammation breaks tolerance to inhaled allergens in mice","volume":"184","author":"van Rijt","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2023.115151_bib111","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1084\/jem.20101563","article-title":"Inflammatory dendritic cells--not basophils--are necessary and sufficient for induction of Th2 immunity to inhaled house dust mite allergen","volume":"207","author":"Hammad","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2023.115151_bib112","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1084\/jem.20071087","article-title":"Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells","volume":"205","author":"Kool","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2023.115151_bib113","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/ni.1740","article-title":"MHC class II\u2013dependent basophil\u2013CD4+ T cell interactions promote TH2 cytokine\u2013dependent immunity","volume":"10","author":"Perrigoue","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib114","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1084\/jem.20070360","article-title":"Induction of high-affinity IgE receptor on lung dendritic cells during viral infection leads to mucous cell metaplasia","volume":"204","author":"Grayson","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2023.115151_bib115","first-page":"561","article-title":"T-cell priming by type-1and type-2 polarized dendritic cells: the concept of a third signal, Immunol","volume":"20","author":"Kali\u0144ski","year":"1999","journal-title":"Today Off."},{"key":"10.1016\/j.ejmech.2023.115151_bib116","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1476-5381.2009.00151.x","article-title":"The role of histamine H4 receptor in immune and inflammatory disorders","volume":"157","author":"Zampeli","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115151_bib117","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3389\/fphar.2019.00556","article-title":"Pathophysiological role of histamine H4 receptor in cancer: therapeutic implications","volume":"10","author":"Nicoud","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115151_bib118","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1021\/jm0341047","article-title":"The first potent and selective non-imidazole human histamine H4 receptor antagonists","volume":"46","author":"Jablonowski","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib119","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/164_2016_130","article-title":"Clinical development of histamine H4 receptor antagonists","volume":"241","author":"Thurmond","year":"2017","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115151_bib120","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1517\/14728220903188438","article-title":"Histamine H3 and H4 receptors as novel drug targets","volume":"18","author":"Tiligada","year":"2009","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2023.115151_bib121","first-page":"628","article-title":"A new generation of anti-histamines: histamine H4 receptor antagonists on their way to the clinic","volume":"12","author":"Engelhardt","year":"2009","journal-title":"Curr. Opin. Drug Discov. Dev"},{"key":"10.1016\/j.ejmech.2023.115151_bib122","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1021\/cr900166w","article-title":"Targeting the histamine H4 receptor","volume":"111","author":"Marson","year":"2011","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2023.115151_bib123","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2174\/138955711794519519","article-title":"Histamine H4 receptor: a novel target for inflammation therapy","volume":"11","author":"Saravanan","year":"2011","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib124","first-page":"967","article-title":"Azines as histamine H4 receptor antagonists","volume":"4","author":"Lazewska","year":"2012","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ejmech.2023.115151_bib125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1517\/13543776.2012.665447","article-title":"Histamine H4 receptor ligands and their potential therapeutic applications: an update","volume":"22","author":"Kiss","year":"2012","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2023.115151_bib126","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1124\/jpet.103.061754","article-title":"A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties","volume":"309","author":"Thurmond","year":"2004","journal-title":"Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2023.115151_bib127","doi-asserted-by":"crossref","first-page":"6547","DOI":"10.1021\/jm800670r","article-title":"Rotationally constrained 2, 4-diamino-5, 6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models","volume":"51","author":"Cowart","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib128","doi-asserted-by":"crossref","first-page":"5460","DOI":"10.1016\/j.bmcl.2011.06.123","article-title":"Fragment library screening reveals remarkable similarities between the G protein-coupled receptor histamine H4 and the ion channel serotonin 5-HT3A","volume":"21","author":"Verheij","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115151_bib129","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1021\/acs.jmedchem.7b01855","article-title":"Discovery of a novel highly selective histamine H4 receptor antagonist for the treatment of atopic dermatitis","volume":"61","author":"Ko","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib130","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ejmech.2014.06.032","article-title":"Aryl-1, 3, 5-triazine derivatives as histamine H4 receptor ligands","volume":"83","author":"\u0141a\u017cewska","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib131","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.1021\/jm8005959","article-title":"Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands","volume":"51","author":"Altenbach","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib132","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1021\/jm7014217","article-title":"Fragment based design of new H4 receptor\u2212 ligands with anti-inflammatory properties in vivo","volume":"51","author":"Smits","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib133","doi-asserted-by":"crossref","first-page":"7769","DOI":"10.1021\/acs.jmedchem.9b00555","article-title":"Discovery of the oral leukotriene C4 synthase inhibitor (1 S, 2 S)-2-({5-[(5-Chloro-2, 4-difluorophenyl)(2-fluoro-2-methylpropyl) amino]-3-methoxypyrazin-2-yl} carbonyl) cyclopropanecarboxylic acid (AZD9898) as a new treatment for asthma","volume":"62","author":"Munck af Rosensch\u00f6ld","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib134","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/jb\/mvt007","article-title":"A leukotriene C4 synthase inhibitor with the backbone of 5-(5-methylene-4-oxo-4, 5-dihydrothiazol-2-ylamino) isophthalic acid","volume":"153","author":"Ago","year":"2013","journal-title":"J. Biochem."},{"key":"10.1016\/j.ejmech.2023.115151_bib135","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12195-017-0515-6","article-title":"Simulation Study of Interactions between two bioactive components from Zingiber cassumunar and 5-lipoxygenase","volume":"11","author":"Jitapunkul","year":"2018","journal-title":"Cell. Mol. Bioeng."},{"key":"10.1016\/j.ejmech.2023.115151_bib136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2016.02.027","article-title":"4, 5-Diarylisoxazol-3-carboxylic acids: a new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP)","volume":"113","author":"Banoglu","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib137","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ejmech.2016.08.066","article-title":"Inhibition of the enzymes in the leukotriene and prostaglandin pathways in inflammation by 3-aryl isocoumarins","volume":"124","author":"Ramanan","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib138","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/jpet.110.166967","article-title":"Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain","volume":"334","author":"Masferrer","year":"2010","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2023.115151_bib139","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0014-2999(94)90140-6","article-title":"The 5-lipoxygenase inhibitors ZD2138 and ZM230487 are potent and selective inhibitors of several antigen-induced Guinea-pig pulmonary responses","volume":"257","author":"Kusner","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115151_bib140","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejmech.2018.08.098","article-title":"Design, synthesis and identification of novel substituted 2-amino thiazole analogues as potential anti-inflammatory agents targeting 5-lipoxygenase","volume":"158","author":"Sinha","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib141","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1126\/science.1197203","article-title":"The structure of human 5-lipoxygenase","volume":"331","author":"Gilbert","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115151_bib142","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/jm501185j","volume":"58","author":"Takahashi","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib143","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1021\/jm501531v","article-title":"Discovery of AZD6642, an inhibitor of 5-lipoxygenase activating protein (FLAP) for the treatment of inflammatory diseases","volume":"58","author":"Lemurell","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib144","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1021\/ml100029k","article-title":"The discovery of setileuton, a potent and selective 5-lipoxygenase inhibitor","volume":"1","author":"Ducharme","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115151_bib145","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1016\/j.bmc.2019.06.040","article-title":"5-Lipoxygenase as a drug target: a review on trends in inhibitors structural design, SAR and mechanism based approach","volume":"27","author":"Sinha","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib146","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1021\/acs.jnatprod.1c00982","article-title":"Structure\u2013activity relationship studies of new sinapic acid phenethyl ester analogues targeting the biosynthesis of 5-lipoxygenase products: the role of phenolic moiety, ester function, and bioisosterism","volume":"85","author":"Touaibia","year":"2022","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejmech.2023.115151_bib147","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1126\/science.1197203","article-title":"The structure of human 5-lipoxygenase","volume":"331","author":"Gilbert","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115151_bib148","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1021\/jm050801i","article-title":"Design and synthesis of novel 2-amino-5-hydroxyindole derivatives that inhibit human 5-lipoxygenase","volume":"49","author":"Landwehr","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib149","doi-asserted-by":"crossref","first-page":"7580","DOI":"10.1016\/j.bmc.2010.08.047","article-title":"Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors","volume":"18","author":"Song","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib150","first-page":"c15","article-title":"Synthesis and biological evaluation of N-Aryl-5-aryloxazol-2-amine derivatives as 5-lipoxygenase inhibitors","author":"Suh","year":"2015","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2023.115151_bib151","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ejmech.2006.03.014","article-title":"Substituted 2-phenyl-benzimidazole derivatives: novel compounds that suppress key markers of allergy","volume":"41","author":"Richards","year":"2006","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib152","doi-asserted-by":"crossref","first-page":"6451","DOI":"10.1021\/jm049288j","article-title":"Novel 2-(substituted phenyl) benzimidazole derivatives with potent activity against IgE, cytokines, and CD23 for the treatment of allergy and asthma","volume":"47","author":"Richards","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib153","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ejmech.2015.11.048","article-title":"Exploring the role of chloro and methyl substitutions in 2-phenylthiomethyl-benzoindole derivatives for 5-LOX enzyme inhibition","volume":"108","author":"Peduto","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib154","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ejmech.2016.10.046","article-title":"Optimization of benzoquinone and hydroquinone derivatives as potent inhibitors of human 5-lipoxygenase","volume":"127","author":"Peduto","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib155","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bcp.2016.04.019","article-title":"The 5-lipoxygenase inhibitor RF-22c potently suppresses leukotriene biosynthesis in cellulo and blocks bronchoconstriction and inflammation in vivo","volume":"112","author":"Schaible","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115151_bib156","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1021\/jm800588x","article-title":"Novel and potent inhibitors of 5-lipoxygenase product synthesis based on the structure of pirinixic acid","volume":"51","author":"Werz","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib157","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0968-0896(02)00531-X","article-title":"Substituted heterocyclic thiourea compounds as a new class of anti-allergic agents inhibiting IgE\/Fc\u03b5RI receptor mediated mast cell leukotriene release","volume":"11","author":"Venkatachalam","year":"2003","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib158","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/14756366.2019.1569647","article-title":"Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4+ cells","volume":"34","author":"Choi","year":"2019","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib159","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1096\/fj.07-8653com","article-title":"Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism","volume":"21","author":"Levy","year":"2007","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejmech.2023.115151_bib160","doi-asserted-by":"crossref","first-page":"6451","DOI":"10.1021\/jm049288j","article-title":"Novel 2-(substituted phenyl) benzimidazole derivatives with potent activity against IgE, cytokines, and CD23 for the treatment of allergy and asthma","volume":"47","author":"Richards","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib161","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.bmcl.2015.01.063","article-title":"Discovery of 7-azaindole derivatives as potent Orai inhibitors showing efficacy in a preclinical model of asthma","volume":"25","author":"Esteve","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib162","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1476-5381.1994.tb17072.x","article-title":"Inhibition by SK&F 96365 of Ca2+ current, IL-2 production and activation in T lymphocytes","volume":"113","author":"Chung","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115151_bib163","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1476-5381.1996.tb15722.x","article-title":"Extracellular site for econazole-mediated block of Ca2+ release-activated Ca2+ current (Icrac) in T lymphocytes","volume":"119","author":"Christian","year":"1996","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115151_bib164","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0022-3565(25)24706-1","article-title":"The antiproliferative and antimetastatic compound L651582 inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release","volume":"257","author":"Felder","year":"1991","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2023.115151_sref165","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1016\/j.bmc.2006.03.024","article-title":"Novel potent and selective calcium-release-activated calcium (CRAC) channel inhibitors. Part 1: synthesis and inhibitory activity of 5-(1-methyl-3-trifluoromethyl-1H-pyrazol-5-yl)-2-thiophenecarboxamides","volume":"14","author":"Yonetoku","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib165a","doi-asserted-by":"crossref","first-page":"5370","DOI":"10.1016\/j.bmc.2006.03.039","article-title":"Novel potent and selective calcium-release-activated calcium (CRAC) channel inhibitors. Part 2: synthesis and inhibitory activity of aryl-3-trifluoromethylpyrazoles","volume":"14","author":"Yonetoku","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib166","doi-asserted-by":"crossref","first-page":"9457","DOI":"10.1016\/j.bmc.2008.09.047","article-title":"Novel potent and selective Ca2+ release-activated Ca2+ (CRAC) channel inhibitors. Part 3: synthesis and CRAC channel inhibitory activity of 4\u2032-[(trifluoromethyl) pyrazol-1-yl] carboxanilides","volume":"16","author":"Yonetoku","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115151_bib167","first-page":"22","article-title":"Quercetin: a versatile flavonoid, Internet","volume":"2","author":"Lakhanpal","year":"2007","journal-title":"J. Medical Update"},{"key":"10.1016\/j.ejmech.2023.115151_bib168","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.cbi.2014.10.021","article-title":"Shikonin, a constituent of Lithospermum erythrorhizon exhibits anti-allergic effects by suppressing orphan nuclear receptor Nr4a family gene expression as a new prototype of calcineurin inhibitors in mast cells, Chem","volume":"224","author":"Wang","year":"2014","journal-title":"Biol. Interact."},{"key":"10.1016\/j.ejmech.2023.115151_bib169","first-page":"1","article-title":"Structure-activity relationships of baicalein and its analogs as novel TSLP inhibitors","volume":"9","author":"Park","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2023.115151_bib170","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/s41590-019-0524-9","article-title":"TSLP: from allergy to cancer","volume":"20","author":"Corren","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib171","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/j.1476-5381.2009.00362.x","article-title":"The K+ channels KCa3. 1 and Kv1. 3 as novel targets for asthma therapy","volume":"157","author":"Bradding","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115151_bib172","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.clim.2017.03.014","article-title":"Prolonged immunomodulation in inflammatory arthritis using the selective Kv1. 3 channel blocker HsTX1 [R14A] and its PEGylated analog","volume":"180","author":"Tanner","year":"2017","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ejmech.2023.115151_bib173","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2174\/187152811797200641","article-title":"Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases","volume":"10","author":"Beeton","year":"2011","journal-title":"Inflamm. Allergy - Drug Targets"},{"key":"10.1016\/j.ejmech.2023.115151_bib174","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1111\/bph.15441","article-title":"Identification of WP1066, an inhibitor of JAK2 and STAT3, as a KV1. 3 potassium channel blocker","volume":"178","author":"Li","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115151_bib175","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1124\/mol.105.015669","article-title":"Design of PAP-1, a selective small molecule Kv1. 3 blocker, for the suppression of effector memory T cells in autoimmune diseases","volume":"68","author":"Schmitz","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115151_bib176","doi-asserted-by":"crossref","first-page":"15492","DOI":"10.1096\/fj.202000861RR","article-title":"Blockade of Kv1. 3 potassium channel inhibits CD8+ T cell\u2010mediated neuroinflammation via PD\u20101\/Blimp\u20101 signaling","volume":"34","author":"Zhao","year":"2020","journal-title":"FASEB"},{"key":"10.1016\/j.ejmech.2023.115151_bib177","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1124\/molpharm.121.000480","article-title":"Mechanisms underlying the inhibition of KV1. 3 channel by scorpion toxin ImKTX58","volume":"102","author":"Zhang","year":"2022","journal-title":"Mol. Pharmacol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423000661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423000661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:04:02Z","timestamp":1777529042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423000661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":178,"alternative-id":["S0223523423000661"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115151","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of allergy: Overview of synthetic anti-allergy small molecules in medicinal chemistry","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115151"}}